20 years ago there was not the same focus on curing diseases in the pharmaceutical industry as there is today, according to Dr. Thomas Kerscher.
“It is not like that anymore. Today they go for the cure. Because there is still a lot of money to be made from a cure for, say, diabetes,” says the doctor, who is VP of Immunology and Respiratory in Takeda Pharmaceuticals.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app